TERN - Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity.

Sector

Healthcare

Industry

Biotechnology

Market Cap

$4.77B

Beta

-0.38

52-Week Range

2.655-53.19

CEO

Amy L. Burroughs

Employees

59

IPO Date

Feb 5, 2021

Exchange

NASDAQ

TERN Options Snapshot

Options pricing data for TERN is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.

What This Page Covers

The TERN overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.